Ramakrishna Venugopalan
Tracked across 3 events · 18 articles · First seen May 20, 2026 · Last active Aug 23, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: As CEO of Continuity Biosciences, Ramakrishna Venugopalan announced the initiation of the clinical trial, highlighting the company's mission to transform solid tumor therapy delivery.
May 20, 2026 · 6 articles
Domestic
Impact: YSRCP leader who condemned the arrest in a joint statement.
Aug 23, 2026 · 6 articles
Business
Impact: Ramakrishna Venugopalan is Co-Founder and CEO of Continuity Biosciences; the event does not directly affect him.
Jul 30, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Ramakrishna Venugopalan live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard